Elan invites vocal critic onto its board

Forget the proxy fight. Elan decided to bypass the wrangle and simply appoint two dissidents to its board voluntarily. Jack Schuler, a former president of Abbott Laboratories who's also been a fierce critic of the Irish company's management, will stand for election under the company banner next month. On Schuler's recommendation, Elan also nominated ex-Eli Lilly CEO Vaughn Bryson for a seat.

Schuler and other shareholders have been quite vocal in their criticism of Elan and its top execs. The critics have picked on everything from the execs' frequent use of company planes to what they see as wronghanded marketing of Elan's primary drug, Tysabri. One key criticism: Elan management doesn't have enough commercial-pharma experience to maximize drug sales and profits.

So it's no accident that the two new board nominees are Big Pharma alums. In announcing the nominations, Elan Chairman Kyran McLaughlin said the men would "greatly strengthen the commercial pharmaceutical experience on the Elan Board."

Is CEO Kelly Martin worried? After all, Schuler has publicly called for Martin's head on a platter; he'd like the CEO replaced by a new leader who has pharma marketing experience. If so, Martin isn't saying. In a public appearance Wednesday, he did say that Elan is in the final phases reviewing its "strategic options," including a possible sale or partnership. That strategic review, incidentally, has also drawn Schuler's fire. So we'll see whether those options go anywhere--and whether Martin goes, too.

- see the Elan release
- find the Irish Times coverage
- check out the story from RTE
- read the Reuters article

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Incyte and Novartis' Jakafi is eying a nod in chronic graft vs. host disease—and it may just have the data to get it done.

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.